Comparison Between Two Different Dosages of Remifentanil During Colonoscopy
This study has been completed.
Sponsor:
Ospedale San Raffaele
Information provided by (Responsible Party):
Agostoni Massimo, Fondazione SanRaffaele del Monte Tabor
ClinicalTrials.gov Identifier:
NCT01229527
First received: October 26, 2010
Last updated: January 2, 2012
Last verified: January 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this randomized double-blind trial is to define the correct dosage of Remifentanil during operative and diagnostic endoscopic procedures. In particular we want to analyze if the administration of Remifentanil by PCSA (Patient Controlled Sedation and Analgesia) is a good method during colonoscopy, evaluating pain control, discharge time and side effects.
90 patients undergoing colonoscopy will be enrolled.
| Condition | Intervention | Phase |
|---|---|---|
|
Colonoscopy |
Drug: Remifentanil Drug: Meperidine |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver) Primary Purpose: Supportive Care |
| Official Title: | Comparison Between Two Different Dosages of Remifentanil Administered by PCSA (Patient Controlled Sedation and Analgesia) and Meperidine During Colonoscopy: A Randomized Double-Blind Trial |
Resource links provided by NLM:
Further study details as provided by Ospedale San Raffaele:
Primary Outcome Measures:
- Discharge Time, the Time to Reach a Modified Aldrete Score ≥18 [ Time Frame: > 0 minutes ] [ Designated as safety issue: No ]Ten key parameters (Activity, Respiration, Circulation, Consciousness, O2 Saturation, Dressing, Pain, Ambulation, Fasting-feeding, Urine Output)are included in the Modified Aldrete Score. The maximum and minimum score for each parameter is respectively 2 and 0. The maximum total score is 20 and patient can be discharged when the total score is ≥18.
Secondary Outcome Measures:
- Patient's Satisfaction [ Time Frame: After the end of colonoscopy (when patients were completely awake) and 24 h after the procedure via telephone ] [ Designated as safety issue: No ]The degree of satisfaction about the quality of sedation was measured with VAS (Visual Analog Scale) where 0 means no satisfaction and 100 means maximum satisfaction.
| Enrollment: | 90 |
| Study Start Date: | April 2009 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Remifentanil RS1 |
Drug: Remifentanil
Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
|
| Experimental: Remifentanil RS2 |
Drug: Remifentanil
Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
|
| Active Comparator: Meperidine |
Drug: Meperidine
Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult Patients
- Diagnostic and Operative Colonoscopy
- ASA Physical Status I-II
Exclusion Criteria:
- Age < 18 years
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Agostoni Massimo, Medical Doctor, Fondazione SanRaffaele del Monte Tabor |
| ClinicalTrials.gov Identifier: | NCT01229527 History of Changes |
| Other Study ID Numbers: | PCSA/Remi 2009 |
| Study First Received: | October 26, 2010 |
| Results First Received: | September 19, 2011 |
| Last Updated: | January 2, 2012 |
| Health Authority: | Italy: Ministry of Health |
Keywords provided by Ospedale San Raffaele:
|
Colonoscopy Remifentanil Sedation |
Additional relevant MeSH terms:
|
Meperidine Remifentanil Analgesics, Opioid Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents |
Therapeutic Uses Central Nervous System Depressants Adjuvants, Anesthesia Narcotics Hypnotics and Sedatives Anesthetics, Intravenous Anesthetics, General Anesthetics |
ClinicalTrials.gov processed this record on May 19, 2013